Moderna is the latest company to produce a promising RSV vaccine

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 40 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 97%

United States News News

United States United States Latest News,United States United States Headlines

The experimental respiratory syncytial virus vaccine prevented most infections in older adults in a Phase 3 clinical trial

Moderna’s disclosure this week that its respiratory syncytial virus vaccine prevented most infections in older adults in a clinical trial further sets the stage for a competitive new market ahead of next winter’s cold season.

The company’s stock MRNA gained 3.6% in trading on Wednesday, the day after Moderna said in a news release that its experimental RSV vaccine had an efficacy rate of 83.7% in adults 60 and older. The full data set is expected to be shared at an unnamed medical meeting in the future. There are currently no RSV vaccines for adults or children, but the attention brought to vaccine development, including messenger RNA technology, as a result of the COVID-19 pandemic revitalized interest in RSV vaccines in what could be a $5 billion market. Though RSV causes regular cold symptoms in most people, it’s of particular concern when it comes to infants, who breathe exclusively through their noses, and older adults, who are at a higher risk of developing lung infections or pneumonia.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

I have 5 Moderna Covid vaccines. I'll get this one too as soon as I can.

Amazing news

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in US

United States United States Latest News, United States United States Headlines